BioTuesdays

Category - Markets

X4 Pharma
Markets

Cantor starts X4 Pharma at OW; PT $3

Cantor Fitzgerald launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with an “overweight” rating and a 12-month price target of $3. The stock closed at 80 cents on Dec. 22. X4 is a clinical-stage biopharmaceutical...

December 22, 2022
MediWound Logo
Markets

Maxim starts MediWound at buy; PT $25

Maxim Group initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and $25 price target. The stock closed at $11 on Dec. 21. MediWound is a commercial-stage company developing a bromelain-based platform to...

December 22, 2022
New-Amsterdam-Logo
Markets

SVB starts NewAmsterdam Pharma at OP; PT $19

SVB Securities initiated coverage of NewAmsterdam Pharma (NASDAQ:NAMS) with an “outperform” rating and $19 price target. The stock closed at $11.31 on Dec. 19. “We believe there is a place for NewAmsterdam’s...

December 20, 2022
Acurx-Pharma-Logo
Markets

HCW starts Acurx Pharma at buy; PT $14

H.C. Wainwright launched coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $14 price target. The stock closed at $3.83 on Dec. 16. Acurx is a clinical stage biopharmaceutical company focused on...

December 19, 2022
Point Biopharma Logo
Markets

Raymond James starts POINT Biopharma at OP; PT $10

Raymond James initiated coverage of POINT Biopharma (NASDAQ:PNT) with an “outperform” rating and price target of $10 target. The stock closed at $6.61 on Dec. 13. POINT is a precision oncology company focused on the...

December 14, 2022
ARS-Pharma-Logo
Markets

SVB starts ARS Pharma at OP; PT $14

SVB Securities launched coverage of ARS Pharmaceuticals (NASDAQ:SPRY) with an “outperform” rating and $14 price target. The stock closed at $7.12 on Dec. 12. ARS is developing neffy, an intranasal epinephrine product in...

December 13, 2022
Pardes Biosciences Logo
Markets

JMP starts Pardes Biosciences at MO; PT $9

JMP Securities initiated coverage of Pardes Biosciences (NASDAQ:PRDS) with a “market outperform” rating and price target of $9. The stock closed at $1.15 on Dec. 12. Pardes is developing PBI-0451 as a potential novel...

December 13, 2022
Affimed Logo
Markets

HCW starts Affimed at buy; PT $6

H.C. Wainwright launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and $6 price target. The stock closed at $2.04 on Dec. 9. Affimed is a clinical-stage biotechnology company focused on developing innate...

December 12, 2022